Is Dana Farber Cancer Institute Efficient?
Dana Farber Cancer Institute has an Efficiency Score of 87/100 (A), spending 78% of revenue on programs. CEO compensation: $0.
This page answers a common question about U.S. nonprofit financial efficiency: Is Dana Farber Cancer Institute Efficient?. The answer below pulls directly from IRS Form 990 filings — the public-disclosure document every U.S. tax-exempt organization must file annually — and the LakeQuality efficiency rubric that combines program-spending, executive-compensation, and financial-stability factors into a single grade. Why this matters: every U.S. taxpayer subsidizes the nonprofit sector indirectly — donations are tax-deductible, nonprofit income is exempt, and many nonprofit employees benefit from sector-specific tax provisions. The public-disclosure regime exists specifically to give donors and policy-makers the data they need to judge whether the subsidy is well-spent on a given organization.
The detailed answer below uses the actual Form 990 numbers, explains how to read them, and translates the technical accounting into the donor-relevant version of the question.
Dana Farber Cancer Institute is a medical research nonprofit based in Boston, Massachusetts with IRS EIN 042263040. According to its Form 990 filing for tax year 2023, the organization reported $3.4B in total revenue, $3.0B in total expenses, and $4.7B in net assets.
Of total expenses, 78% ($2.3B) went directly to programs — the core mission work. The remainder covers administrative overhead, fundraising, and other operating costs. This program ratio falls within the typical range for established nonprofits.
CEO compensation at Dana Farber Cancer Institute was $0 in 2023, representing approximately 0.0 basis points (0.00%) of total revenue. Our Efficiency Score of 87/100 weights program spending ratio (50%), revenue growth consistency (20%), fund reserves (20%), and CEO compensation ratio (10%), producing a grade of A.
Key Data
| Metric | Value |
|---|---|
| Efficiency Score | 87/100 (A) |
| Program Spending Ratio | 78% |
| Total Revenue | $3.4B |
| Total Expenses | $3.0B |
| CEO Compensation | $0 |
| Category | Medical Research |
Other Medical Research Nonprofits
Frequently Asked Questions
Dana Farber Cancer Institute has an Efficiency Score of 87/100 (A), spending 78% of revenue on programs. CEO compensation: $0.
Dana Farber Cancer Institute spent $2.3B on programs in 2023, representing 78% of total expenses.
The CEO of Dana Farber Cancer Institute received $0 in reported compensation for tax year 2023, according to IRS Form 990.
Dana Farber Cancer Institute reported $3.4B in total revenue for tax year 2023, with $4.7B in net assets.
Our Efficiency Score weights four factors from IRS 990 data: program spending ratio (50%), revenue growth consistency (20%), fund reserves (20%), and CEO compensation ratio (10%). Dana Farber Cancer Institute scored 87/100 (grade A).
Dana Farber Cancer Institute has an Efficiency Score of 87/100 (A), spending 78% of revenue on programs. CEO compensation: $0.